[go: up one dir, main page]

WO2009041113A1 - NK CELL HAVING Fc RECEPTOR GENE INTRODUCED THEREIN, METHOD FOR PRODUCTION OF THE SAME, AND METHOD FOR ASSAY ON ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY USING THE SAME - Google Patents

NK CELL HAVING Fc RECEPTOR GENE INTRODUCED THEREIN, METHOD FOR PRODUCTION OF THE SAME, AND METHOD FOR ASSAY ON ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY USING THE SAME Download PDF

Info

Publication number
WO2009041113A1
WO2009041113A1 PCT/JP2008/058670 JP2008058670W WO2009041113A1 WO 2009041113 A1 WO2009041113 A1 WO 2009041113A1 JP 2008058670 W JP2008058670 W JP 2008058670W WO 2009041113 A1 WO2009041113 A1 WO 2009041113A1
Authority
WO
WIPO (PCT)
Prior art keywords
cell
same
receptor gene
antibody
assay
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/058670
Other languages
French (fr)
Japanese (ja)
Inventor
Natsuhiko Sugimura
Yuji Mishima
Kiyohiko Hatake
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japanese Foundation for Cancer Research
Olympus Corp
Original Assignee
Japanese Foundation for Cancer Research
Olympus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japanese Foundation for Cancer Research, Olympus Corp filed Critical Japanese Foundation for Cancer Research
Priority to JP2009534209A priority Critical patent/JP5282040B2/en
Publication of WO2009041113A1 publication Critical patent/WO2009041113A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The object is: to produce uniform effector cells for an ADCC assay in large quantity without taking a toll on the body of a healthy volunteer or a subject; and to construct an ADCC assay system by utilizing the effector cells. An effector cell strain can be established, which has an Fc receptor expressed on the surface of the cell and can be continuously cultured (sub-cultured). More specifically, a cell strain derived from an NK cell can be established, which has an Fc receptor gene integrated into the chromosome of the cell by using a recombinant viral vector.
PCT/JP2008/058670 2007-09-28 2008-05-09 NK CELL HAVING Fc RECEPTOR GENE INTRODUCED THEREIN, METHOD FOR PRODUCTION OF THE SAME, AND METHOD FOR ASSAY ON ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY USING THE SAME Ceased WO2009041113A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009534209A JP5282040B2 (en) 2007-09-28 2008-05-09 Method for assaying antibody-dependent cytotoxicity using Fc receptor gene-transferred NK cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-254099 2007-09-28
JP2007254099 2007-09-28

Publications (1)

Publication Number Publication Date
WO2009041113A1 true WO2009041113A1 (en) 2009-04-02

Family

ID=40511014

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/058670 Ceased WO2009041113A1 (en) 2007-09-28 2008-05-09 NK CELL HAVING Fc RECEPTOR GENE INTRODUCED THEREIN, METHOD FOR PRODUCTION OF THE SAME, AND METHOD FOR ASSAY ON ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY USING THE SAME

Country Status (2)

Country Link
JP (1) JP5282040B2 (en)
WO (1) WO2009041113A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013519360A (en) * 2010-02-11 2013-05-30 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 3DADCCNKFACS assay
JP2015223143A (en) * 2014-05-29 2015-12-14 国立大学法人富山大学 NK cell line for evaluating the ability of TCR to induce cytotoxic activity and method for producing the same
CN110546265A (en) * 2017-02-09 2019-12-06 因达普塔治疗公司 Engineered Natural Killer (NK) cells and compositions and methods thereof
CN112980851A (en) * 2021-03-03 2021-06-18 上海奥浦迈生物科技股份有限公司 Method for efficiently detecting fusion protein/antibody Fc segment incapable of mediating ADCC (ADCC-mediated cancer cell mediated cytotoxicity) and CDC (CDC) activities
JP2021522839A (en) * 2018-05-14 2021-09-02 インダプタ セラピューティクス インコーポレイテッド A subset of human natural killer cells with enhanced antibody-directed immune response
US12152253B2 (en) 2012-04-18 2024-11-26 Board Of Trustees Of Michigan State University Natural killer cells with enhanced immune response
US12410402B2 (en) 2018-11-21 2025-09-09 Indapta Therapeutics, Inc. Methods for expansion of natural killer (NK) cell subset and related compositions and methods

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7426661B2 (en) * 2018-12-17 2024-02-02 株式会社カネカ Screening method for cells that produce specific antigen-specific antibodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004147565A (en) * 2002-10-30 2004-05-27 Japan Science & Technology Agency Immortalized natural killer cell line
US20060292156A1 (en) * 2004-07-10 2006-12-28 Campbell Kerry S Genetically modified human natural killer cell lines

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002329196B2 (en) * 2001-07-06 2008-08-07 Senomyx, Inc. Human olfactory nucleotide-gated ion channels
KR20050100371A (en) * 2003-01-13 2005-10-18 에모리 유니버시티 Methods of detecting gene expression in normal and cancerous cells
JP2007053926A (en) * 2005-08-23 2007-03-08 Hamamatsu Kagaku Gijutsu Kenkyu Shinkokai Highly sensitive method for detecting phototoxicity, and phototoxicity detection kit

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004147565A (en) * 2002-10-30 2004-05-27 Japan Science & Technology Agency Immortalized natural killer cell line
US20060292156A1 (en) * 2004-07-10 2006-12-28 Campbell Kerry S Genetically modified human natural killer cell lines

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LIAO F. ET AL.: "Cross-linking of FcyRIIIA on natural killer cells results in tyrosine phosphorylation of PLC-yl and PLC-y2.", THE JOURNAL OF IMMUNOLOGY, vol. 150, no. 7, 1993, pages 2668 - 2674 *
SUCK G. ET AL.: "KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity.", EXPERIMENTAL HEMATOLOGY, vol. 33, no. 10, 2005, pages 1160 - 1171, XP005108371, DOI: doi:10.1016/j.exphem.2005.06.024 *
YUJI MISHIMA ET AL.: "Establishment of reproducible ADCC assay system.", 66TH PROCEEDINGS OF THE JAPANESE CANCER ASSOCIATION, vol. 340, 25 August 2007 (2007-08-25), pages 750 *
YUJI MISHIMA: "Kotai Iyaku no Hotai Izonsei, Kotai Izonsei Satsusaibo Koka", PHARMA MEDICA, vol. 25, no. 3, 10 March 2007 (2007-03-10), pages 9 - 13 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013519360A (en) * 2010-02-11 2013-05-30 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 3DADCCNKFACS assay
US10330669B2 (en) 2010-02-11 2019-06-25 Hoffmann-La Roche Inc. 3D ADCC NK FACS assay
US12152253B2 (en) 2012-04-18 2024-11-26 Board Of Trustees Of Michigan State University Natural killer cells with enhanced immune response
JP2015223143A (en) * 2014-05-29 2015-12-14 国立大学法人富山大学 NK cell line for evaluating the ability of TCR to induce cytotoxic activity and method for producing the same
CN110546265A (en) * 2017-02-09 2019-12-06 因达普塔治疗公司 Engineered Natural Killer (NK) cells and compositions and methods thereof
JP2020507349A (en) * 2017-02-09 2020-03-12 インダプタ セラピューティクス インコーポレイテッド Engineered natural killer (NK) cells and compositions and methods thereof
US11920156B2 (en) 2017-02-09 2024-03-05 Indapta Therapeutics, Inc. Engineered natural killer (NK) cells and compositions and methods thereof
JP2021522839A (en) * 2018-05-14 2021-09-02 インダプタ セラピューティクス インコーポレイテッド A subset of human natural killer cells with enhanced antibody-directed immune response
US12410402B2 (en) 2018-11-21 2025-09-09 Indapta Therapeutics, Inc. Methods for expansion of natural killer (NK) cell subset and related compositions and methods
CN112980851A (en) * 2021-03-03 2021-06-18 上海奥浦迈生物科技股份有限公司 Method for efficiently detecting fusion protein/antibody Fc segment incapable of mediating ADCC (ADCC-mediated cancer cell mediated cytotoxicity) and CDC (CDC) activities

Also Published As

Publication number Publication date
JP5282040B2 (en) 2013-09-04
JPWO2009041113A1 (en) 2011-01-20

Similar Documents

Publication Publication Date Title
WO2009041113A1 (en) NK CELL HAVING Fc RECEPTOR GENE INTRODUCED THEREIN, METHOD FOR PRODUCTION OF THE SAME, AND METHOD FOR ASSAY ON ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY USING THE SAME
NZ584893A (en) PORCINE DC-SIGN, ICAM-3 AND LSECtin AND USES THEREOF
WO2009114702A3 (en) Recombinant production of authentic human proteins using human cell expression systems
WO2010148203A3 (en) Producer cells for replication competent retroviral vectors
AU2009209251A8 (en) Stabilized Angiopoietin-2 antibodies and uses thereof
WO2011116922A9 (en) Thermoreactive substrate with microgels, method for its preparation, and culture method for biological cells
MX2010002990A (en) Production of isoprenoids.
WO2008070082A3 (en) Stem-progenitor cell specific micro-ribonucleic acids and uses thereof
PT2386640E (en) Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells
EP2584034B8 (en) Pluripotent stem cell differentiation by using human feeder cells
WO2005080551A3 (en) Stem cells
NZ595476A (en) Plant snf1-related protein kinase gene
MY146612A (en) Production of isoprenoids
WO2008118212A3 (en) In vivo delivery of double stranded rna to a target cell
WO2005069840A3 (en) Processes for producing a fermentation product
WO2011059920A3 (en) Methods of generating neural stem cells
WO2011061629A3 (en) Yeast strains producing mammalian-like complex n-glycans
IL184696A (en) Recombinant co-expression of vitamin k epoxide reductase subunit 1 to improve vitamin k dependent protein expression
WO2016007570A3 (en) Engineered invariant natural killer t (inkt) cells and methods of making and using thereof
WO2010068897A3 (en) Stem cell enhanced protein products and uses thereof
WO2009147538A3 (en) Dense and erect panicle gene and uses thereof
EP4556467A3 (en) Methods for array synthesis
MX336473B (en) 3d adcc nk facs assay.
UA92157C2 (en) Process for production of growth hormone
MX2014001396A (en) A pentose sugar fermenting cell.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08752553

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009534209

Country of ref document: JP

122 Ep: pct application non-entry in european phase

Ref document number: 08752553

Country of ref document: EP

Kind code of ref document: A1